Salud
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation
![](https://univciencia.com/wp-content/uploads/2024/05/rt-ultimo4-MEZPMQ.jpeg)
In a trial involving patients with COPD and type 2 inflammation shown by elevated blood eosinophil counts, treatment with dupilumab reduced disease exacerbation and improved lung function.
In a trial involving patients with COPD and type 2 inflammation shown by elevated blood eosinophil counts, treatment with dupilumab reduced disease exacerbation and improved lung function. The New England Journal of Medicine: Search Results in Allergy/Immunology